Opus Genetics, Inc.: Director FFB RDF sold 556,000 shares

What happened

• Foundation Fighting Blindness Retinal Degeneration Fund (reported as a director by deputization) sold 556,000 shares of Opus Genetics in an open market or private sale on Sep 30, 2026 for a total of $2,755,981. The filing reports a weighted average price of $4.96 per share.

Key details

• Transaction date and prices: Sep 30, 2026; prices ranged from $4.95 to $5.29 and the price reported is a weighted average of $4.96 (footnote F1).
• Transaction type and code: sale (code S), described as open market or private sale.
• Shares owned after the transaction: not reported in this filing.
• Footnote on ownership and voting: the filing says Foundation Fighting Blindness, Inc. is the sole member of the reporting fund (RDF) and may be deemed to beneficially own the securities; RDF has the power to vote and dispose of its securities and its board makes voting and investment decisions, subject to certain approval rights of FFB (footnote F2).
• Remarks: the filing says the reporting persons may be deemed a director by deputization because Adrienne Graves, PhD and Jean Bennett, MD, PhD were appointed to the issuer's board and Dr. Graves is chair of RDF and a member of FFB's board.

Why it may matter

• This was a direct sale of shares (not an option exercise, grant, gift, or tax withholding).
• The filing describes RDF and FFB's relationship and voting/dispositive powers but does not state that RDF is a 10% owner.
• This filing does not show why the insider traded or why the company acted.